Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome

International Journal of Clinical Practice

Volumn 67, Issue 5, 2013, Pages 427-434

  Kuo, H C ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ANALGESIA; ARTICLE; BLADDER CAPACITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CYSTALGIA; CYSTOMETRY; CYSTOSCOPIC HYDRODISTENTION; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FEMALE; FUNCTIONAL BLADDER CAPACITY; GLOBAL RESPONSE ASSESSMENT; GLOMERULATION GRADE; HEMATURIA; HUMAN; INCLUDING PROBLEM INDEX; INCLUDING SYMPTOM INDEX; INTERSTITIAL CYSTITIS; MALE; MAXIMAL BLADDER CAPACITY; MICTURITION DISORDER; O LEARY SANT SYMPTOM SCORE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; SCORING SYSTEM; THERAPY; URINARY TRACT INFECTION; URINE RETENTION; URODYNAMICS; VISUAL ANALOG SCALE;

ADMINISTRATION, INTRAVESICAL; ANALGESICS; ANTI-INFLAMMATORY AGENTS; BOTULINUM TOXINS, TYPE A; CHRONIC DISEASE; CYSTITIS, INTERSTITIAL; FEMALE; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; NEUROTOXINS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URODYNAMICS;

EID: 84876495429     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12113     Document Type: Article

References (30)

1. Hanno PM, Sant GR,. Clinical highlights of the national Institute of Diabetes and Digestive and Kidney Diseases/Interstitial Cystitis Association scientific conference on interstitial cystitis. Urology 2001; 57 (Suppl. 6A): 2-6. (Pubitemid 33733958)
2. Shie JH, Kuo HC,. Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int 2011; 108: E136-41.
3. Brady CM, Apostolidis A, Harper M, et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004; 93: 770-6. (Pubitemid 38497026)
4. 3-deficient mice. Nature 2000; 407: 1011-5.
5. Cayan S, Coskun B, Bozlu M, Acar D, Akbay E, Ulusoy E,. Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol Res 2003; 30: 399-404. (Pubitemid 36285659)
6. Steers WD, Tuttle JB,. Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006; 3: 101-10. (Pubitemid 43239267)
7. Rapp DE, Turk KW, Bales GT, Cook SP,. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006; 175: 1138-42. (Pubitemid 43200117)
8. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB,. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain response in rats. J Urol 2004; 172: 1529-32. (Pubitemid 39249763)
9. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006; 175: 2341-4. (Pubitemid 43668538)
10. Khera M, Somogyi GT, Kiss S, Kiss S, Boone TB, Smith CP., Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004; 45: 987-93. (Pubitemid 39164923)
11. Apostolidis A, Papat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injection of botulinum A toxin for human detrusor overactivity. J Urol 2005; 173: 977-83.
12. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510-5. (Pubitemid 38376219)
13. Smith CP, Radziszewski P, Borkowski A, Boone TB, Chancellor MB., Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 871-5. (Pubitemid 39469494)
14. Kuo HC,. Preliminary results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. Urol Int 2005; 75: 170-4.
15. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M., Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: A pilot study. Eur Urol 2006; 49: 704-9. (Pubitemid 43374735)
16. Cui M, Aoki KR,. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia 2000; 20: 414-8.
17. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E., Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 2008; 179: 1031-4.
18. Hanno P,. (1998). Interstitial cystitis and related diseases. In:, Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology, 7th edn. Philadelphia: WB Saunders, Co., pp. 631-62.
19. NIDDK workshop of interstitial cystitis, Besthesda, Maryland, USA, Aug 28-29, 1987.
20. Lubeck DP, Whitmore K, Sant GR, Alvarez-Horine S, Lai C,. Psychometric validation of the O'Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology 2001; 57 (Suppl. 1): 62-6. (Pubitemid 33733969)
21. Nickel JC, Barkin J, Forrest J, Mosbaugh PG, Hernandez-Graulau J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005; 65: 654-8. (Pubitemid 40522993)
22. Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulphate and oral hydroxyzine in patients with interstitial cystitis. J Urol 2003; 170: 810-5. (Pubitemid 36999563)
23. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78. (Pubitemid 34195211)
24. Parsons CL,. The potassium sensitivity test: a new gold standard for diagnosing and understanding the pathophysiology of interstitial cystitis. J Urol 2009; 182: 432-44.
25. Kuo HC, Chancellor MB,. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009; 104: 657-61.
26. Cui M, Khanijou S, Rubino J, Aoki KR,. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107: 125-33. (Pubitemid 38058707)
27. Liu HT, Kuo HC,. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007; 70: 463-8.
28. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58: 360-5.
29. Yamada T, Nishimura M, Mita H,. Increased number of apoptotic endothelial cells in bladder of interstitial cystitis patients. World J Urol 2007; 25: 407-13.
30. Kiuchi H, Tsujimura A, Takao T, et al. Increased vascular endothelial growth factor expression in patients with bladder pain syndrome/ interstitial cystitis: its association with pain severity and glomerulations. BJU Int 2009; 104: 826-31.